Objective: Oxygen toxicity is thought to contribute to the development of bronchopulmonary dysplasia (BPD). Oxidant injury leads to formation of F 2 -isoprostanes (F 2 -IsoP). We hypothesized that urinary excretion of the stable metabolite of F 2 -IsoP, 8-iso-PGF 2a , would be higher in infants who develop BPD than those who did not.
Introduction
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease of prematurity, is a complication of premature birth. 1 Infants with BPD have prolonged hospital stays and incur higher expenditures when compared to those without BPD. 2 No tests are currently available to predict which infants will develop BPD. Availability of such identifiers would facilitate further research, and later therapies, to be targeted to these more susceptible infants.
BPD is believed to result from a combination of oxygen toxicity, barotrauma from mechanical ventilation and inflammatory mediators. 3 Oxygen toxicity results from the effects of reactive oxygen species, such as superoxide radical, hydroxyl radical and singlet oxygen, on lung cells with oxidative injury to DNA, proteins and lipids. Premature infants are less prepared to cope with the oxygen-rich environment of extrauterine life, as their antioxidant mechanisms are underdeveloped compared to those infants born at term. 4, 5 Lipids, especially those in the cell membrane, are susceptible to the high reactivity of reactive oxygen species. Lipid peroxidation results, whereby the double bonds of unsaturated fatty acids in the cell membrane are attacked by excess free radicals and results in the formation of isoprostanes. Although many classes of isoprostanes are formed, F 2 -isoprostanes (F 2 -IsoP) are the most stable and have been studied most extensively in the literature. 6 Hence, they are an index of choice for assessment of the lipid peroxidation effects of oxidant stress in vivo.
Although F 2 -IsoP and 8-iso-PGF 2a have been identified as an index of lipid peroxidation in numerous adult pulmonary diseases, [7] [8] [9] [10] limited data are available on the role of F 2 -IsoP as a marker of BPD in premature infants. We hypothesized that premature infants <30-weeks gestation that later develop BPD would have elevated levels of urinary 8-iso-PGF 2a early in life, when compared to those infants who do not develop BPD. Furthermore, as extremely low birth weight (ELBW) infants are least likely to be developmentally prepared for extrauterine life, 4 we theorized that isoprostane levels would be inversely correlated with gestational age (GA). Collection of urine specimens Urine was collected from each infant in the first postnatal week and weekly thereafter until 36 weeks postmenstrual age. Urine was collected by placing a cotton ball in the diaper, allowing the infant to spontaneously void, and then aspirating the contents from the cotton ball into a sterile syringe. If the cotton ball became contaminated with stool, the specimen was discarded and a new cotton ball was placed. The specimens were then promptly refrigerated at 41C for no more than 24 h and transferred to a freezer at À801C until analyzed.
Materials and Methods

Subjects
Quantitation of 8-iso-PGF 2a
Urine samples were analyzed for 8-iso-PGF 2a content using gas chromatography negative ion chemical ionization mass spectrometry (NICI-MS).
11 Each sample was prepared with the addition of an internal standard, d 4 8-iso-PGF 2a (Cayman Chemical, Ann Arbor, MI, USA), purified with C 18 and silica Sep-Paks (Waters Corporation, Milford, MA, USA), and dried under N 2 at 371C for approximately 25 min. Subsequently, the sample was esterified with 10% pentafluorobenzyl bromide (PFBB) solution in acetonitrile (ACN), 10% diisopropylethylamine (DIPE) in ACN was then added and the sample was dried under N 2 . The samples were reconstituted with a 3:2 methanol:chloroform solution and extracted via thin layer chromatography (TLC) before analysis on a 5973 Mass Selective Detector (MSD) (Agilent Technologies, Wilmington, DE, USA) at 190 to 3001C, utilizing a 15 m DB -1701 (0.25 mm) column. Results are reported in nanograms of isoprostanes normalized to urinary creatinine excretion to minimize variability of results owing to the highly variable urine excretion in the early newborn period.
Creatinine determination Urine creatinine (cr) was determined via enzymatic colorimetric assay (Roche Diagnostics; Indianapolis, IN, USA).
Statistical analyses
As urinary isoprostane levels in ELBW infants have not been previously published, data from Stier et al. 12 were used in sample size calculation. The mean urinary isoprostane level for infants with a mean GA of 31 weeks was 0.2917 ng/mmol cr (95% confidence interval (CI) 0.08 to 0.55) (standard deviation (s.d.) 0.1175). Assuming a 1 s.d. (50%) increase in 8-iso-PGF 2a in those infants who developed BPD and 80% power, a sample size of 18 infants in each group would be necessary to detect a significant difference.
Baseline characteristics were analyzed using two-tailed unpaired t-tests. A P-value of 0.05 was considered statistically significant.
Data are reported as mean±s.d. Urinary 8-iso-PGF 2a excretion was determined on two or more occasions during the first week in a quarter of the entire cohort and in the third week in the entire cohort to examine the effects of postnatal age and BPD on urinary 8-iso-PGF 2a excretion. Repeated measures analysis of variance (ANOVA) and paired t-tests were performed as appropriate to assess the effects of time and development of BPD on 8-iso-PGF 2a excretion. Owing to the skewness of the data, analyses were performed on both raw and log-transformed data.
Results
Forty infants were enrolled prospectively of which 24 developed BPD (M: F 16:8) and 16 (M: F 8:8) did not. The mean GA of the BPD group was significantly less than the non-BPD group (26.5±1.5 weeks vs 27.8±0.93 weeks, P ¼ 0.004). Similarly, the BW of the BPD group was less than the non-BPD group (891±254 g vs 1123±228 g, P ¼ 0.006) ( Table 1) .
The mean urinary 8-iso-PGF 2a concentration in the first postnatal week in those infants who developed BPD was 0.95±0.68 ng/mmol cr, compared to 0.83±0.41 ng/mmol cr in infants who did not develop BPD (P ¼ 0.53; 95% CI, À0.5 to 0.26). Similarly, the mean 8-iso-PGF 2a level in the third week after birth was 1.06±0.93 ng/mmol cr versus 1.23±1.12 ng/mmol cr in the BPD and non-BPD groups, respectively (P ¼ 0.62; 95% CI, -0.49 to 0.83) ( Table 2 ). Furthermore, we found no statistically significant relationships either between samples taken during the first week or first and third week, irrespective of the subsequent development of BPD. Log transformation of the data did not affect the results.
Post hoc analyses of the data using the NICHD/NHLBI classification of BPD 3 revealed greater urinary 8-iso-PGF 2a excretion in the first week of life in infants who subsequently developed BPD when compared with infants who did not develop BPD; however, the differences were not statistically significant, as the study was not powered to seek such differences. 
Discussion
Contrary to our hypothesis, we found no significant differences in urinary isoprostane excretion during the first and third week of life in preterm infants who did and did not develop BPD. Our findings are in contrast with those of Ahola et al., 13 who reported that plasma levels of isoprostanes increase in the first week of life in preterm infants who later develop BPD.
Several reasons may explain our findings. First, plasma isoprostane levels are inversely related to GA. It is possible that the effect of prematurity on isoprostane synthesis exceeds that of the hyperoxic lung injury associated with the development of BPD. In our study, GA and BW of infants who developed BPD were lower than those who did not (Table 1) . However, the lack of difference in urinary isoprostane excretion persisted when our analysis controlled for GA and BW. Second, renal filtration of isoprostane may be rate-limiting in preterm infants, and thus does not reflect plasma levels as has been reported in pre-eclamptic pregnant women who have high plasma levels but low urinary excretion.
14 Third, we measured isoprostanes using gas chromatography/mass spectrometry (GC-MS), which is a very sensitive and specific method compared to enzyme immunoassay (EIA) that has been used by other investigators. 13, 15 To our knowledge, this is the first study to attempt to measure isoprostanes by GC-MS in the urine of preterm infants with regard to BPD. Differences in methodology (GC-MS vs EIA) may explain differences in results between the study by Ahola et al. 13 on plasma isoprostanes and ours on urine isoprostanes. For example, it is possible that the EIA assay recognizes fragments or forms that are not detected by the GC-MS method. 16, 17 Although our hypothesis was not confirmed, this pilot investigation provides useful information. Our results add to the limited information on urinary F 2 -IsoP in preterm infants and help to establish normative data for urinary excretion in extremely premature infants. In the only published report of urinary isoprostane excretion in preterm infants, Stier et al. 12 found that urinary 8-iso-PGF 2a excretion was 0.29 ng/mmol cr (range 0.08 to 0.55 ng/mmol cr), which was lower than our infants. However, infants in our study were more immature and smaller. This difference in urinary results may reflect the inverse relationship of plasma isoprostane levels with GA. 18 In summary, we did not find differences in urinary 8-iso-PGF 2a excretion in the neonatal period between those infants who developed BPD and those who did not. It is possible that the large standard deviation in the levels of 8-iso-PGF 2a excretion along with the small number of patients in our study may have resulted in a Type II error; a larger study with a greater number of patients may reveal statistical differences between the two groups, which would support the hypothesis that lipid peroxidation occurs as part of the pathogenesis of BPD. However, the marked variability of both plasma isoprostane levels 13 and urinary isoprostane excretion (this study) that result in a large overlap in the ranges of the results of infants who do or do not develop BPD limit the utility of isoprostanes as a predictive marker for BPD. 
